



**FY2005
RESULT BRIEFING
Supplementary Information**

May 17th, 2006

<Contact>

Miraca Holdings Inc.
IR Public Relations Group

Phone: 03-5909-3337 Fax: 03-5909-3336

URL : <http://www.miraca-holdings.co.jp/>

Consolidated Financial Highlights

	2005/1-3 3-month Results	FY2005 Revised Forecast (Rev.10/27/2005)	FY2005 Results
Net sales (millions of yen)	35,446	140,000	138,357
Operating income (millions of yen)	1,592	13,200	13,283
Income from ordinary operations (millions of yen)	1,596	13,500	13,671
Net income (millions of yen)	167	7,900	8,064
Net income per share (yen)	3.68	132.80	135.91
Net income per share (diluted) (yen)	3.41	—	133.73
Total assets (millions of yen)	120,583	—	122,894
Shareholders' equity (millions of yen)	48,516	—	75,428
Shareholders' equity per common share (yen)	1,066.33	—	1,260.64
Return on shareholder's equity (ROE) (%)	0.4	—	13.0
Return on asset (ROA) (%)	1.3	—	11.2
Capital ratio (%)	40.2	—	61.4
Number of consolidated subsidiaries	31	—	25

Note: Due to the fiscal year change from *January-December* to *April-March*, 2005/1-3 is irregular three-month fiscal period from January 2005 to March 2005.

Note: The following companies are excluded from consolidation for FY2005;

- **SBS Inc.** and **SRL Tokyo Medical Inc.(STM)** as a result of merger with SRL Inc. on 2006/4/1.
- **Rejoice, Inc.** and **Rejoice Pharmacy, Inc.** as a result of divestiture of dispensing pharmacy business closed on 2005/4/1.
- **Japan Clinical Pharmacology Laboratories Ltd.(JCPL)** as a result of sales of JCPL's share owned by SRL and allocation of new JCPL shares to Sogo Clinical Pharmacology Co.,Ltd.

<p>* FY2003: January 2003 - December 2003 * FY2004: January 2004 - December 2004 * FY2005: April 2005 - March 2006 * FY2006: April 2006 - March 2007</p>

Segment Results-1 (Consolidated)

(Some portion of *Lab Testing Related* segment is newly categorized as and transferred to *Preventive Medicine Related* segment.)

<Performance by Business Segment>

(billions of yen)

	FY2003 Reference	FY2004 Reference	FY2005 Results	FY2006 Forecast
Net sales	144.8	144.8	138.4	144.5
In Vitro Diagnostics	29.6	28.4	29.9	32.0
Clinical Lab Testing	93.3	90.9	90.8	92.5
Other	21.8	25.5	17.7	20.0
(Clinical Trials)	3.8	4.9	4.0	5.3
(Sterilizing)	6.4	7.1	8.1	8.8
(Dispensing Pharmacy)	7.1	8.4	—	—
(Preventive Medicine Related)	4.5	5.1	5.6	5.9
Operating income	11.8	10.8	13.3	15.5
In-Vitro Diagnostics	7.7	6.7	7.3	7.5
Clinical Lab Testing	2.7	2.3	4.4	6.0
Other	1.4	1.8	1.6	2.0
(Clinical Trials)	0.3	0.2	-0.0	0.3
(Sterilizing)	0.2	0.4	0.5	0.6
(Dispensing Pharmacy)	0.3	0.3	—	—
(Preventive Medicine Related)	0.6	0.9	1.1	1.1

Note: Figures are rounded to the nearest 100 million yen.

Segment Results-2 (Consolidated)

<R&D Expenses>

(billions of yen)

	FY2003 Reference	FY2004 Reference	FY2005 Results	FY2006 Forecast
R&D Expenses	3.6	4.2	4.4	4.9
In Vitro Diagnostics	3.1	3.7	4.0	4.3
Clinical Lab Testing (incl. related business)	0.5	0.4	0.4	0.5
Others	—	—	—	—

Note: Figures are rounded to the nearest 100 million yen.

Note: A portion of **Others** segment is included in **Clinical Lab Testing** segment.

<Capital Expenditure>

(billions of yen)

	FY2003 Reference	FY2004 Reference	FY2005 Results	FY2006 Forecast
Capital Expenditure	9.8	7.5	9.9	12.9
In Vitro Diagnostics	2.1	2.6	3.2	3.9
Clinical Lab Testing	7.2	4.5	6.2	8.4
Others	0.5	0.3	0.4	0.6

Note: Figures are rounded to the nearest 100 million yen.

Note: Capital expenditure is aggregation of tangible assets (property, plant, and equipment), intangible assets and long-term prepaid expenses.

Note: A portion of **Others** segment is included in **Clinical Lab Testing** segment.

Note: MiracaHD is included in **Others** segment.

<Depreciation & Amortization>

(billions of yen)

	FY2003 Reference	FY2004 Reference	FY2005 Results	FY2006 Forecast
Depreciation & Amortization	8.3	8.7	8.4	8.7
In Vitro Diagnostics	2.1	2.2	2.4	2.5
Clinical Lab Testing	5.9	6.2	5.7	5.8
Other	0.3	0.3	0.3	0.4

Note: Figures are rounded to the nearest 100 million yen.

Note: A portion of **Others** segment is included in **Clinical Lab Testing** segment.

Note: MiracaHD is included in Others

Note: MiracaHD is included in **Others** segment.

<Number of Employees>

	FY2003 Reference	FY2004 Reference	FY2005 Results
Total employees (full-time)	4,968	5,130	4,623
In Vitro Diagnostics	739	752	752
Clinical Lab Testing	3,396	3,466	3,086
Other	833	912	776
(Clinical Trials)	117	178	141
(Sterilizing)	412	472	551
(Preventive Medicine Related)	304	262	84
Miraca HD	—	—	9

*Decrease of number of employees in FY2005 is mainly due to divestiture of dispensing pharmacy business and exclusion of JCPL from consolidation.

Share of Stock

<Stock Information >

	FY2003 Year-end	FY2004 Year-end	2005/1-3 Year-end	FY2005 Year-end
Number of shares issued (thousands of share)	43,160	44,790	47,805	60,366
Number of shareholders	6,533	5,134	5,372	9,805
Stock price (yen)	1,235	1,455	1,685	2,405
Aggregate market value of listed stock (billions of yen)	53.3	65.1	80.6	145.2

Note: Issued number of shares includes treasury stocks.

<Treasury Stock>

	FY2003	FY2004	2005/1-3 3-month	FY2005
Number of treasury stocks	78,607	2,298,402	2,310,908	532,539

Note: 1.8 million shares of treasury stocks was allocated to sock swap with SRL on 2005/4/1.

<Cash Dividends per Share>

	FY2003	FY2004	2005/1-3 3-month	FY2005
Half-year dividends (yen)	6.0	7.0	-	10.0
Year-end dividends (yen)	7.0	8.0	4.0	18.0
Annual dividends per share (yen)	13.0	15.0	4.0	28.0

[Reference - 1]

1. Breakdown of Clients by Hospital sizes for 2005

	Total in Japan	Fujirebio's clients	SRL Group's clients
500 beds or more	358	329 (91.9%)	306 (85.5%)
400-499 beds	234	209 (89.3%)	187 (79.9%)
300-399 beds	526	399 (75.9%)	359 (68.3%)
200-299 beds	760	491 (64.6%)	395 (52.0%)
100-199 beds	2,310	1118 (48.4%)	824 (35.7%)
20-99 beds	3,588	1,253 (34.9%)	768 (21.4%)

Note: The number of hospital is according to the annual research by SRL. Hospitals with partial order are included in above numbers.

2. Number of LUMIPULSE in the Market

	2003/12	2004/12	2005/3	2006/3
<i>Forte</i>	850	950	980	1,050
<i>Presto</i>	-	5	5	20
<i>S</i>	-	-	-	5

Note: The number of Lumipulse is rounded to the nearest 10.

3. Contracted Laboratory Management within Hospitals

	FY2003	FY2004	2005/1-3 3-month	FY2005
Number of facilities	149	156	157	158
Sales (billion yen)	12.7	13.7	3.4	14.4

Note: Number of facilities = Branch Lab + FMS (Facility Management Service)

Note: The above sales include income from leasing equipments, devices, etc.

Note: Due to the fiscal year change from *January-December* to *April-March*, 2005/1-3 is irregular three-month fiscal period from January 2005 to March 2005.

[Reference - 2 Clinical Lab Testing]

1. Sales Breakdown by Hospital Management (SRL)

	FY2003	FY2004	2005/1-3 3-month	FY2005
National	10.4%	10.1%	10.6%	10.0%
Municipal	31.7%	31.1%	30.7%	30.3%
Union	5.9%	6.1%	6.0%	6.3%
Non profit corporation	6.7%	6.3%	5.7%	5.9%
Medical corporation	10.9%	10.4%	10.9%	10.5%
Private university hospital	11.8%	11.9%	12.0%	12.2%
Others	22.6%	24.1%	24.1%	24.8%
Total	100.0%	100.0%	100.0%	100.0%

2. Sales Breakdown by Hospital Size (SRL)

	FY2003	FY2004	2005/1-3 3-month	FY2005
500 beds or more	41.4%	43.1%	44.1%	44.1%
400-499 beds	13.5%	13.4%	13.4%	14.1%
300-399 beds	16.1%	15.5%	15.3%	15.0%
200-299 beds	14.0%	13.3%	13.0%	12.7%
100-199 beds	11.6%	11.2%	11.0%	10.7%
20-99 beds	3.4%	3.5%	3.2%	3.4%
Total	100.0%	100.0%	100.0%	100.0%

3. Sales Breakdown by Disease Category (SRL)

	FY2003	FY2004	2005/1-3 3-month	FY2005
Malignant tumor	17.1%	16.8%	15.8%	15.6%
Infection disease (excluding viral hepatitis)	9.2%	9.1%	8.9%	8.9%
Allergy	6.1%	5.5%	7.1%	5.5%
Hepatic disease (excluding Malignant tumor)	5.8%	5.2%	5.1%	5.2%
Autoimmune disease	5.5%	5.5%	5.4%	5.5%
Thyroid disease	4.5%	4.3%	3.9%	4.1%
Cardiac disease, Hyperlipidemia	4.6%	4.5%	4.5%	4.4%
General test	16.9%	18.0%	17.9%	19.9%
Others	30.3%	31.1%	31.4%	30.9%
Total	100.0%	100.0%	100.0%	100.0%

4. Sales of Gene Based Testing

	FY2003	FY2004	2005/1-3 3-month	FY2005
Sales (billion yen)	2.8	3.0	0.7	3.3

Note: The above sales composed of human gene test, chromosomal test, infectious disease test (non-health insurance).

Note: Due to the fiscal year change from *January-December* to *April-March*, 2005/1-3 is irregular three-month fiscal period from January 2005 to March 2005.